Antitumor hiroshi nagai activities of interleukin-27 on melanoma

Endocrine, Metabolic and Immune Disorders - Drug Targets

Volumn 10, Issue 1, 2010, Pages 41-46

  Nagai, Hiroshi ^a   Oniki, Shuntaro ^a   Fujiwara, Susumu ^a   Xu, Mingli ^b   Mizoguchi, Izuru ^b   Yoshimoto, Takayuki ^b   Chikako, Nishigori ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CXCL9 CHEMOKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 18; INTERLEUKIN 27; JANUS KINASE; STAT PROTEIN; ANTINEOPLASTIC AGENT; C19ORF10 PROTEIN, HUMAN; IL27RA PROTEIN, HUMAN; INTERLEUKIN 17; INTERLEUKIN DERIVATIVE; INTERLEUKIN RECEPTOR;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; BAGG ALBINO MOUSE; CANCER IMMUNOTHERAPY; CYTOTOXIC T LYMPHOCYTE; DRUG MECHANISM; DRUG STRUCTURE; HUMAN; IMMUNOGENICITY; KNOCKOUT MOUSE; MELANOMA; NATURAL KILLER CELL; NONHUMAN; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; CHEMISTRY; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; METHODOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SKIN TUMOR;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-17; INTERLEUKINS; MELANOMA; RECEPTORS, INTERLEUKIN; SKIN NEOPLASMS;

EID: 77950841393     PISSN: 18715303     EISSN: None     Source Type: Journal    
DOI: 10.2174/187153010790827920     Document Type: Review

References (52)

1. Thompson, J.F.; Scolyer, R.A. and Kefford, R.F. (2005) Cutaneous melanoma. Lancet, 365(9640), 687-701.
2. Clemente, C.G.; Mihm, M.C.; Jr. Bufalino, R.; Zurrida, S.; Collini,P. and Cascinelli, N. (1996) Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer, 77(7), 1303-1310.
3. Kageshita, T.; Hirai, S.; Ono, T.; Hicklin, D.J. and Ferrone, S. (1999) Down-regulation of HLA class I antigen-processing molecules in malignant melanoma: association with disease progression. Am. J. Pathol., 154(3), 745-754.
4. Pflanz, S.; Timans, J.C.; Cheung, J.; Rosales, R.; Kanzler, H.; Gilbert, J.; Hibbert, L.; Churakova, T.; Travis, M.; Vaisberg, E.; Blumenschein, W.M.; Mattson, J.D.; Wagner, J.L.; To, W.; Zurawski, S.; McClanahan, T.K.; Gorman, D.M.; Bazan, J.F.; deWaal Malefyt, R.; Rennick, D. and Kastelein, R.A. (2002) IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4(+) T cells. Immunity, 16(6), 779-790.
5. Pflanz, S.; Hibbert, L.; Mattson, J.; Rosales, R.; Vaisberg, E.;Bazan, J.F.; Phillips, J.H.; McClanahan, T.K.; de Waal Malefyt, R. and Kastelein, R.A. (2004) WSX-1 and glycoprotein 130 constitute a signal-transducing receptor for IL-27. J. Immunol., 172(4), 2225-2231.
6. Scheller, J.; Schuster, B.; Hölscher, C.; Yoshimoto, T. and Rose-John, S. (2005) No inhibition of IL-27 signaling by soluble gp130. Biochem. Biophys. Res. Commun., 326(4), 724-728.
7. Chen, Q.; Ghilardi, N.; Wang, H.; Baker, T.; Xie, M.H.; Gurney, A.; Grewal, I.S. and de Sauvage, F.J. (2000) Development of Th1-type immune responses requires the type I cytokine receptor TCCR. Nature, 407(6806), 916-920.
8. Takeda, A.; Hamano, S.; Yamanaka, A.; Hanada, T.; Ishibashi, T.; Mak, T.W.; Yoshimura, A. and Yoshida, H. (2003) Cutting edge:role of IL-27/WSX-1 signaling for induction of T-bet through activation of STAT1 during initial Th1 commitment. J. Immunol.,170(10), 4886-4890.
9. Morishima, N.; Owaki, T.; Asakawa, M.; Kamiya, S.; Mizuguchi,J. and Yoshimoto, T. (2005) Augmentation of effector CD8+ T cell generation with enhanced granzyme B expression by IL-27. J.Immunol., 175(3), 1686-1693.
10. Owaki, T.; Asakawa, M.; Morishima, N.; Hata, K.; Fukai, F.; Matsui, M.; Mizuguchi, J. and Yoshimoto, T. (2005) A role for IL-27 in early regulation of Th1 differentiation. J. Immunol., 175(4),2191-2200.
11. Batten, M.; Li, J.; Yi, S.; Kljavin, N.M.; Danilenko, D.M.; Lucas, S.; Lee, J.; de Sauvage, F.J. and Ghilardi, N. (2006) Interleukin 27 limits autoimmune encephalomyelitis by suppressing the development of interleukin 17-producing T cells. Nat. Immunol., 7(9), 929-936.
12. Stumhofer, J.S.; Laurence, A.; Wilson, E.H.; Huang, E.; Tato, C.M.; Johnson, L.M.; Villarino, A.V.; Huang, Q.; Yoshimura, A.; Sehy, D.; Saris, C.J.; O'Shea, J.J.; Hennighausen, L.; Ernst, M. and Hunter, C.A. (2006) Interleukin 27 negatively regulates the developmentof interleukin 17-producing T helper cells during chronic inflammation of the central nervous system. Nat. Immunol., 7(9), 937-945.
13. Yoshimoto, T.; Yoshimoto, T.; Yasuda, K.; Mizuguchi, J. and Nakanishi, K. (2007) IL-27 suppresses Th2 cell development and Th2 cytokines production from polarized Th2 cells: a novel therapeutic way for Th2-mediated allergic inflammation. J. Immunol.,179(7), 4415-4423.
14. Neufert, C.; Becker, C.; Wirtz, S.; Fantini, M.C.; Weigmann, B.; Galle, P.R. and Neurath, M.F. (2007) IL-27 controls the development of inducible regulatory T cells and Th17 cells via differential effects on STAT1. Eur. J. Immunol., 37(7), 1809-1816.
15. Stumhofer, J.S.; Silver, J.S.; Laurence, A.; Porrett, P.M.; Harris,T.H.; Turka, L.A.; Ernst, M.; Saris, C.J.; O'Shea, J.J. and Hunter, C.A. (2007) Interleukins 27 and 6 induce STAT3-mediated T cell production of interleukin 10. Nat. Immunol., 8(12), 1363-1371.
16. Fitzgerald, D.C.; Zhang, G.X.; El-Behi, M.; Fonseca-Kelly, Z.; Li, H.; Yu, S.; Saris, C.J.; Gran, B.; Ciric, B. and Rostami, A. (2007)Suppression of autoimmune inflammation of the central nervous system by interleukin 10 secreted by interleukin 27-stimulated T cells. Nat. Immunol., 8(12), 1372-1379.
17. Awasthi, A.; Carrier, Y.; Peron, J.P.; Bettelli, E.; Kamanaka, M.; Flavell, R.A.; Kuchroo, V.K.; Oukka, M. and Weiner, H.L. (2007) A dominant function for interleukin 27 in generating interleukin 10-producing anti-inflammatory T cells. Nat. Immunol., 8(12),1380-1389.
18. Hisada, M.; Kamiya, S.; Fujita, K.; Belladonna, M.L.; Aoki, T.; Koyanagi, Y.; Mizuguchi, J. and Yoshimoto, T. (2004) Potent antitumor activity of interleukin-27. Cancer Res., 64(3), 1152-1156.
19. Salcedo, R.; Stauffer, J.K.; Lincoln, E.; Back, T.C.; Hixon, J.A.; Hahn, C.; Shafer-Weaver, K.; Malyguine, A.; Kastelein, R. and Wigginton, J.M. (2004) IL-27 mediates complete regression of orthotopic primary and metastatic murine neuroblastoma tumors: role for CD8+ T cells. J. Immunol., 173(12), 7170-7182.
20. Oniki, S.; Nagai, H.; Horikawa, T.; Furukawa, J.; Belladonna, M.L.; Yoshimoto, T.; Hara, I. and Nishigori, C. (2006) Interleukin-23 and interleukin-27 exert quite different antitumor and vaccine effects on poorly immunogenic melanoma. Cancer Res., 66(12), 6395-6404.
21. Shimizu, M.; Shimamura, M.; Owaki, T.; Asakawa, M.; Fujita, K.; Kudo, M.; Iwakura, Y.; Takeda, Y.; Luster, A.D.; Mizuguchi, J. and Yoshimoto, T. (2006) Antiangiogenic and antitumor activities of IL-27. J. Immunol., 176(12), 7317-7324.
22. Hu, P.; Hu, H.D.; Chen, M.; Peng, M.L.; Tang, L.; Tang, K.F.; Matsui, M.; Belladonna, M.L.; Yoshimoto, T.; Zhang, D.Z.; Xiang, R. and Ren, H. (2009) Expression of interleukins-23 and 27 leads to successful gene therapy of hepatocellular carcinoma. Mol. Immunol., 46(8-9), 1654-1662.
23. Liu, L.; Wang, S.; Shan, B.; Shao, L.; Sato, A.; Kawamura, K.; Li, Q.; Ma, G. and Tagawa, M. (2008) IL-27-mediated activation of natural killer cells and inflammation produced antitumour effects for human oesophageal carcinoma cells. Scand. J. Immunol., 68(1), 22-29.
24. Matsui, M.; Kishida, T.; Nakano, H.; Yoshimoto, K.; Shin-Ya, M.; Shimada, T.; Nakai, S.; Imanishi, J.; Yoshimoto, T.; Hisa, Y. and Mazda, O. (2009) Interleukin-27 activates natural killer cells and suppresses NK-resistant head and neck squamous cell carcinoma through inducing antibody-dependent cellular cytotoxicity. Cancer Res., 69(6), 2523-2530.
25. Leonard, W.J. and O'Shea, J.J. (1998) Jaks and STATs: biological implications. Annu. Rev. Immunol., 16, 293-322.
26. Kamiya, S.; Owaki, T.; Morishima, N.; Fukai, F.; Mizuguchi, J. and Yoshimoto, T. (2004) An indispensable role for STAT1 in IL-27-induced T-bet expression but not proliferation of naive CD4+ T cells. J. Immunol., 173(6), 3871-3877.
27. Voest, E.E.; Kenyon, B.M.; O'Reilly, M.S.; Truitt, G.; D'Amato, R.J. and Folkman, J. (1995) Inhibition of angiogenesis in vivo by interleukin 12. J. Natl. Cancer Inst., 87(8), 581-586.
28. Coughlin, C.M.; Salhany, K.E.; Wysocka, M.; Aruga, E.; Kurzawa, H.; Chang, A.E.; Hunter, C.A.; Fox, J.C.; Trinchieri, G. and Lee,W.M. (1998) Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis.J. Clin. Invest., 101(6), 1441-1452.
29. Cao, R.; Farnebo, J.; Kurimoto, M. and Cao, Y. (1999) Interleukin-18 acts as an angiogenesis and tumor suppressor. FASEB J., 13(15),2195-2202.
30. Watanabe, M.; McCormick, K.L.; Volker, K.; Ortaldo, J.R.;Wigginton, J.M.; Brunda, M.J.; Wiltrout, R.H. and Fogler, W.E.(1997) Regulation of local host-mediated anti-tumor mechanisms by cytokines: direct and indirect effects on leukocyte recruitment and angiogenesis. Am. J. Pathol., 150(5), 1869-1880.
31. Nagai, H.; Hara, I.; Horikawa, T.; Oka, M.; Kamidono, S. and Ichihashi, M. (2002) Gene transfer of secreted-type modified interleukin-18 gene to B16F10 melanoma cells suppresses in vivo tumor growth through inhibition of tumor vessel formation. J. Invest.Dermatol., 119(3), 541-548.
32. Car, B.D.; Eng, V.M.; Schnyder, B.; LeHir, M.; Shakhov, A.N.;Woerly, G.; Huang, S.; Aguet, M.; Anderson, T.D. and Ryffel, B. (1995) Role of interferon-γ in interleukin 12-induced pathology in mice. Am. J. Pathol., 147(6), 1693-1707.
33. Atkins, M.B.; Robertson, M.J.; Gordon, M.; Lotze, M.T.; DeCoste,M.; DuBois, J.S.; Ritz, J.; Sandler, A.B.; Edington, H.D.; Garzone, P.D.; Mier, J.W.; Canning, C.M.; Battiato, L.; Tahara, H. and Sherman, M.L. (1997) Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin. Cancer Res., 3(3), 409-417.
34. Motzer, R.J.; Rakhit, A.; Schwartz, L.H.; Olencki, T.; Malone,T.M.; Sandstrom, K.; Nadeau, R.; Parmar, H. and Bukowski, R. (1998) Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma. Clin. CancerRes., 4(5), 1183-1191.
35. Portielje, J.E.; Kruit, W.H.; Schuler, M.; Beck, J.; Lamers, C.H.;Stoter, G.; Huber, C.; de Boer-Dennert, M.; Rakhit, A.; Bolhuis, R.L. and Aulitzky, W.E. (1999) Phase I study of subcutaneously administered recombinant human interleukin 12 in patients withadvanced renal cell cancer. Clin. Cancer Res., 5(12), 3983-3989.
36. Shinozaki, Y.; Wang, S.; Miyazaki, Y.; Miyazaki, K.; Yamada, H.;Yoshikai, Y.; Hara, H. and Yoshida, H. (2009) Tumor-specific cytotoxic T cell generation and dendritic cell function are differentially regulated by interleukin 27 during development of anti-tumor immunity. Int. J. Cancer., 124(6), 1372-1378.
37. Dibra, D.; Cutrera, J.J.; Xia, X.; Birkenbach, M.P. and Li, S. (2009) Expression of WSX1 in tumors sensitizes IL-27 signalingindependent natural killer cell surveillance. Cancer Res., 69(13), 5505-5513.
38. Yoshimoto, T.; Morishima, N.; Mizguchi, I.; Shimizu, M.; Nagai, H.; Oniki, S.; Oka, M., Nishigori, C. and Mizuguchi, J. (2008) An tiproliferative activity of IL-27 on melanoma. J. Immunol., 180(10), 6527-6535.
39. Sangfelt, O.; Erickson, S. and Grander, D. (2000) Mechanisms of interferon-induced cell cycle arrest. Front. Biosci., 5, D479-D487.
40. Detjen, K.M.; Farwig, K.; Welzel, M.; Wiedenmann, B. and Rosewicz, S. (2001) Interferon γ inhibits growth of human pancreatic carcinoma cells via caspase-1 dependent induction of apoptosis. Gut., 49(2), 251-262.
41. Hobeika, A.C.; Etienne, W.; Cruz, P.E.; Subramaniam, P.S. and Johnson, H.M. (1998) IFNγ induction of p21WAF1 in prostate cancer cells: role in cell cycle, alteration of phenotype and invasivepotential. Int. J. Cancer, 77(1), 138-145.
42. Ruiz-Ruiz, C.; Ruiz de Almodóvar, C.; Rodríguez, A.;Ortiz-Ferrón, G.; Redondo, J.M. and López-Rivas, A. (2004) The up-regulation of human caspase-8 by interferon-γ in breast tumor cells requires the induction and action of the transcription factor interferon regulatory factor-1. J. Biol. Chem., 279(19), 19712-19720.
43. Tomita, Y.; Bilim, V.; Hara, N.; Kasahara, T. and Takahashi, K. (2003) Role of IRF-1 and caspase-7 in IFN-γ enhancement of Fasmediated apoptosis in ACHN renal cell carcinoma cells. Int. J. Cancer, 104(4), 400-408.
44. Merchant, M.S.; Yang, X.; Melchionda, F.; Romero, M.; Klein, R.; Thiele, C.J.; Tsokos, M.; Kontny, H.U. and Mackall, C.L. (2004)Interferon γ enhances the effectiveness of tumor necrosis factorrelated apoptosis-inducing ligand receptor agonists in a xenograft model of Ewing's sarcoma. Cancer Res., 64(22), 8349-8356.
45. Papageorgiou, A.; Lashinger, L.; Millikan, R.; Grossman, H.B.; Benedict, W.; Dinney, C.P. and McConkey, D.J. (2004) Role of tumor necrosis factor-related apoptosis-inducing ligand in interferon-induced apoptosis in human bladder cancer cells. Cancer Res., 64(24), 8973-8979.
46. Ruiz-Ruiz, C.; Muñoz-Pinedo, C. and López-Rivas, A. (2000) Interferon-γ treatment elevates caspase-8 expression and sensitizes human breast tumor cells to a death receptor-induced mitochondriaoperated apoptotic program. Cancer Res., 60(20), 5673-5680.
47. Luster, A.D. and Leder, P. (1993) IP-10, a -C-X-C- chemokine, elicits a potent thymus-dependent antitumor response in vivo. J. Exp. Med., 178(3), 1057-1065.
48. Palmer, K.; Hitt, M.; Emtage, P.C.; Gyorffy, S. and Gauldie, J. (2001) Combined CXC chemokine and interleukin-12 gene transfer enhances antitumor immunity. Gene Ther., 8(4), 282-290.
49. Dorsey, R.; Kundu, N.; Yang, Q.; Tannenbaum, C.S.; Sun, H.;Hamilton, T.A. and Fulton, A.M. (2002) Immunotherapy with interleukin-10 depends on the CXC chemokines inducible protein-10 and monokine induced by IFN-γ. Cancer Res., 62(9), 2606-2610.
50. Feldman, A.L.; Friedl, J.; Lans, T.E.; Libutti, S.K.; Lorang, D.;Miller, M.S.; Turner, E.M.; Hewitt, S.M. and Alexander, H.R. (2002) Retroviral gene transfer of interferon-inducible protein 10 inhibits growth of human melanoma xenografts. Int. J. Cancer, 99(1), 149-153.
51. Sun, Y.; Finger, C.; Alvarez-Vallina, L.; Cichutek, K. andBuchholz, C.J. (2005) Chronic gene delivery of interferoninducible protein 10 through replication-competent retrovirus vectorssuppresses tumor growth. Cancer Gene Ther., 12(11), 900-912.
52. Salcedo, R.; Hixon, J.A.; Stauffer, J.K.; Jalah, R.; Brooks, A.D.;Khan, T.; Dai, R.M.; Scheetz, L.; Lincoln, E.; Back, T.C.; Powell, D.; Hurwitz, A.A.; Sayers, T.J.; Kastelein, R.; Pavlakis, G.N.; Felber, B.K.; Trinchieri, G. and Wigginton, J.M. (2009) Immunologic and therapeutic synergy of IL-27 and IL-2: enhancement of T cell sensitization, tumor-specific CTL reactivity and complete regression of disseminated neuroblastoma metastases in the liverand bone marrow. J. Immunol., 182(7), 4328-4338